Key result
This editorial introduces a special issue on cancer-associated thrombosis, summarizing recent advances in biomarkers, risk assessment models, and the interplay between hemostasis and cancer progression.
Cancer-associated thrombosis is a major cause of mortality and morbidity in cancer patients, complicating treatment and reducing quality of life.
It is firmly established that thromboembolic disease is a common complication of cancer and, overall, venous thromboembolism (VTE) remains the second most common cause of death in cancer patients after the malignancy itself.[1] Besides the direct contribution to cancer-related mortality, cancer-associated thrombosis (CAT) may cause delay or disruption of anticancer treatment. The patient who experiences a cancer-associated VTE will be prescribed anticoagulant treatment, often long-term, which leads to increased number of bleeding events and can be challenging to manage in connection with surgery or antineoplastic agents. Finally, cancer patients report that occurrence of a CAT has a significant negative influence on their quality of life.[2]
No takes yet. Share an insight, caveat, or question.
Gyldenholm et al. (2024) conducted an editorial in Cancer-Associated Thrombosis. This editorial introduces a special issue on cancer-associated thrombosis, summarizing recent advances in biomarkers, risk assessment models, and the interplay between hemostasis and cancer progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: